Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of daily exemestane before surgery in postmenopausal women with endometrial intraepithelial neoplasia, atypical hyperplasia, or low-grade endometrial cancer
2019-001447-40Phase 2Terminated
- Sponsor
- Ospedali Galliera
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exemestane in endometrial hyperplasia (EH), Endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC), sponsored by Ospedali Galliera. Primary endpoint: Absolute change in Ki-67 expression. Started Apr 2021; status: terminated.
02
Drugs
exemestane
03
Conditions
endometrial hyperplasia (EH)Endometrial intraepithelial neoplasia (EIN)endometrial cancer (EC)
Beyond the preview
Go deeper on 2019-001447-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001447-40.